Esperance Pharmaceuticals is a company developing a class of targeted anticancer drugs. It uses its cationic lytic peptide (CLYPTM) technology to provide drugs that seek and destroy cancer cells, including cells known to be resistant to chemotherapeutic drugs, without harming normal cells. The company is focused on the development of EP-100 for the treatment of women with ovarian cancer and breast cancer.